The conclusions I reach when I imagine life without ALS

PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). The status aims to accelerate the development of therapies for rare diseases, or…

An arm of the HEALEY ALS platform trial testing Neurizon Therapeutics’ experimental therapy NUZ-001 as a treatment for amyotrophic lateral sclerosis (ALS) is expanding enrollment from 160 to as many as 240 participants. The decision follows enrollment that exceeded original expectations and the absence of another HEALEY regimen…

Regulatory authorities in the Netherlands have given the green light for a clinical trial testing Ability Neurotech‘s experimental brain-implantable technology as a way to restore communication and speech in people with amyotrophic lateral sclerosis (ALS). The study is designed to assess whether the system can support independent communication…

French actor Pierre Deny, known for his role in the Netflix streaming series “Emily in Paris,” has died from amyotrophic lateral sclerosis (ALS) at age 69. “It is with deep emotion that we announce the passing of Pierre Deny, which occurred this Monday following a sudden and severe case of…

Every May for the past five years, the nonprofit I AM ALS hosts a summit to raise ALS awareness, the hallmark of which is a display of 6,000 small blue flags planted on the National Mall in Washington, D.C. Each flag represents a person who is living with…

Living in areas with a moderate amount of green space appears to reduce the likelihood of developing amyotrophic lateral sclerosis (ALS) — but both very low and very high levels of greenness may increase the odds for different reasons, according to a study from Italy. The findings “may have…